

# PAPERS & POSTERS

## Clinical Research

A GLOBAL SERVICE PROVIDER OF PRECLINICAL AND CLINICAL RESEARCH IN OPHTHALMOLOGY

### Topical low dose preservative-free hydrocortisone reduces signs and symptoms in patients with chronic dry eye: a randomized clinical trial

KALLAB M (a), SZEGEDI S (a), HOMMER N (a), STEGMANN H (a), KAYA S (b), WERKMEISTER RM (a), SCHMIDL D (a), SCHMETTERER L (a)(c)(d)(e), and GARHÖFER G (a)

**Adv. Ther.** 2020; 37: 329–341 doi: 10.1007/s12325-019-01137-8 (collaboration)

(a) Medical University of Vienna, Vienna, Austria - (b) Department of Ophthalmology, Hietzing Hospital, Vienna, Austria - (c) Singapore Eye Research Institute, Singapore, Singapore - (d) Nanyang Technological University, Singapore, Singapore - (e) Ophthalmology and Visual Sciences Academic Clinical Program, Duke-NUS Medical School, Singapore, Singapore

....#2020-228



### Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study

ECONOMOU M (a), KOLSTAD LAUKELAND H (b,c), GRABSKA-LIBEREK I (d), and ROULAND JF (e)

**Clinical Ophthalmol.** 2018; 12 : 2399–2407 (collaboration)

(a) St Erik's Eye Hospital, Stockholm, Sweden - (b) University Hospital, Trondheim, Norway - (c) Norwegian University of Science and Technology, Trondheim, Norway - (d) Ophthalmology Clinic Postgraduate Centre of Medical Education, Warszawa, Poland - (e) Claude Huriez Hospital, Lille, France

....#2018-217



### Report of the TFOS/ARVO symposium on global treatments for dry eye disease: an unmet need

SULLIVAN D (a), HAMMITT K (b), SCHAUMBERG D (c), SULLIVAN B (d), BEGLEY C (e), GJORSTRUP P (f), GARRIGUE JS (g), NAKAMURA M (h), QUENTRIC Y (i), BARABINO S (j), DALTON M (k), and NOVACK G (l)

**The Ocular Surface.** Special Article. April 2012; 10(2) : 108-116

(a) SCHEPENS EYE RESEARCH INSTITUTE, Massachusetts Eye and Ear Infirmary and Department of Ophthalmology, Harvard Medical School, Boston, MA, USA - (b) SJOGREN'S SYNDROME FOUNDATION, Bethesda, MD, USA - (c) BRIGHAM AND WOMEN'S HOSPITAL and HARVARD MEDICAL SCHOOL, Boston, MA, USA - (d) TEARLAB Corporation, San Diego, CA, USA - (e) SCHOOL OF OPTOMETRY, Indiana University, Bloomington, IN, USA - (f) RESOLVYX Pharmaceuticals, Bedford, MA, USA - (g) NOVAGALI Pharma, Evry, France - (h) SANTEN Pharmaceutical Co, Nara, Japan - (i) IRIS PHARMA, La Gaude, France - (j) CLINICA OCULISTICA, University of Genoa, Genoa, Italy - (k) DALTON & ASSOCIATES, Reading, PA, USA - (l) PHARMA LOGIC, San Rafael, CA, USA

....#2012-175

### Explorations et imagerie rétinienne

**BENCHABOUNE M**

**STO meeting 2011**; Tunis - Tunisia. Oral Communication in French

....#2011-164

### Adaptive optics imaging in age-related macular degeneration

GOCHO-NAKASHIMA K (a), **BENCHABOUNE M** (b), ULLERN M (a), LAMORY B (c), CHATEAU N (c), SAHEL JA (a), and PAQUES M (a)

**EVER meeting 2011**; Crete - Greece. Oral Communication

(a) INSERM 503, Paris, France - (b) IRIS PHARMA, La Gaude, France - (c) IMAGINE EYES, Orsay, France

....#2011-163



### In vivo microscopic imaging of drusen using adaptive optics

LAMORY B (a), NAKASHIMA K (b), **BENCHABOUNE M** (b,c), ULLERN M (b), VUAILLAT E (a), SAHEL JA (b), and PAQUES M (b)

**ARVO meeting 2011**; Fort Lauderdale, FL - USA. ARVO e-abstract No. 4469/A218

(a) Imagine Eyes, Orsay, France - (b) INSERM 503, Paris, France - (c) IRIS PHARMA, La Gaude, France

....#2011-162

### Dry Eye Syndrome: the regulatory challenge. Clinical trial and regulatory challenges faced by Iris Pharma in the development of dry eye therapies

**QUENTRIC Y**

**TFOS Global Dry Eye Experts' meeting 2010**; Florence - Italy. Oral Communication

....#2010-159

### Rôle des oligoéléments (Se, Zn) dans la prévention de la DMLA : le point en 2010

**BENCHABOUNE M.**

**SFVB/SFERETE/ATERET meeting 2010**; Monastir - Tunisia. Oral Communication (in French)

....#2010-158






### Associer les patients atteints de DMLA à la recherche, est-ce possible ?

**BENCHABOUNE M**

**Vu et Entendu.** 2009; 2 : 4

....#2008-155



- Tear concentrations of azithromycin following topical administration of a single dose of azithromycin 0.5%, 1.0%, and 1.5% eyedrops (T1225) in healthy volunteers** .....#2008-151  
 CHIAMBARETTA F, GARRAFFO R, **ELENA PP**, POULIQUEN P, DELVAL L, RIGAL D, DUBRAY C, GOLDSCHMIDT P, TABBARA K, and COCHEREAU I  
**Eur. J. Ophthalmol.** 2008; 18(1) : 13-20 
- La recherche biomédicale en France : ce qui a changé depuis 2004** .....#2008-150  
 CLERGET-CHOSSAT N (a), CAILLAUD T (a), and **ELENA PP** (a)  
**J. Fr. Ophtalmol.** 2008; 31 : 80-86  
 (a) IRIS PHARMA, Nice, France 
- Trend of prescription of silicon hydrogel lens by ophthalmologists and lens assessment by patients** .....#2007-144  
 CROS BOIDEVEZI M (a), STEVE L (a), JOUVENCEL R (a), and **CLIROPTHHA** (b)  
**29th IEEE EMBS Annual International Conference 2007**; Lyon - France  
 (a) CIBA Vision France, Paris, France - (b) CLIROPTHHA, Nice, France
- A new method for intra ocular pressure in vivo measurement: first clinical trials** .....#2007-143  
 DUBOIS P, ZEMMOURI J, ROULAND JF, **ELENA PP**, LOPES R, and PUECH P  
**29th IEEE EMBS Annual International Conference 2007**; Lyon – France 
- The role of the CROs in the ophthalmology drug development in Europe** .....#2006-142  
**ELENA PP(a)**  
**ISOPT meeting 2006**; Berlin - Germany  
 (a) CLIROPTHHA, Nice, France 
- Improvement of dry eye symptoms with polyunsaturated fatty acids** .....#2006-139  
 GARCHER C, PASSEMARD M, LAFONTAINE PO, VIAU S, JOFFRE C, **ELENA PP**, POULIQUEN P, BAUDOUIIN C, and BRON AM  
**ARVO meeting 2006**; Fort Lauderdale, FL - USA. **Invest. Ophthalmol. Vis. Sci.** 2006; 47: ARVO e-abstract No. 236
- Amélioration de la symptomatologie chez des patients atteints de sécheresse oculaire et traités oralement par des acides gras polyinsaturés. Improvement of dry eye symptoms with polyunsaturated fatty acids** .....#2006-138  
 GARCHER C, PASSEMARD M, VIAU S, JOFFRE C, LAFONTAINE PO, **ELENA PP**, POULIQUEN P, BAUDOUIIN C, and BRON AM  
**SFO meeting 2006**; Paris - France. Oral communication No. 220 
- Enquête prospective, nationale, multicentrique auprès de 345 patients anciens et nouveaux porteurs sur la santé oculaire, la performance visuelle et la satisfaction des lentilles O<sub>2</sub> OPTIX TORIC** .....#2006-137  
 DELFOUR-MALECAZE M (a), STEVE L (b), and **CLIROPTHHA** (c)  
**Réflexions Ophtalmol.** 2006; 95 : 50-53  
 (a) Toulouse, France (b) CIBA Vision France, Paris, France - (c) CLIROPTHHA, Nice, France
- Improvement of dry eye symptoms with polyunsaturated fatty acids** .....#2006-136  
**Amélioration de la symptomatologie chez des patients atteints de sécheresse oculaire et traités oralement par des acides gras polyinsaturés**  
 CREUZOT C, PASSEMARD M, VIAU S, JOFFRE C, POULIQUEN P, **ELENA PP**, BRON A, and BRIGNOLE F  
**J. Fr. Ophtalmol.** 2006; 29(8):868-73 
- Trend of prescription of silicon hydrogel lens by ophthalmologists and lens assessment by patients** .....#2006-135  
 CROS BOIDEVEZI M (a), STEVE L (a), JOUVENCEL R (a), **CLIROPTHHA** (b)  
**36th ECLSO Congress 2006**; Dubrovnik - Czech Republic. Abstract No. 9  
 (a) CIBA Vision France, Paris, France - (b) CLIROPTHHA, Nice, France
- Etude comparative des implants Alcon asphériques (SN60WF) versus standards (SN60AT)** .....#2006-134  
 MONTARD M  
**Safir meeting 2006**; Paris - France (collaboration)
- Improvement of dry eye symptoms with polyunsaturated fatty acids** .....#2006-133  
 GARCHER C (a), PASSEMARD M (a), LAFONTAINE PO (a), VIAU S (b), JOFFRE C (b), **ELENA PP** (c), POULIQUEN P (d), BAUDOUIIN C (e), and BRON AM (a)  
**EVER meeting 2006**; Vilamoura - Portugal, free paper No. 3155 and poster No. 335  
 (a) Hopital General, Dijon, France - (b) INRA - Eye and Nutrition Unit, Dijon, France (c) CLIROPTHHA, Nice, France (d) Laboratoires THEA, Clermont-Ferrand, France - (e) CHNO XV-XX, Paris, France
- Improvement of dry eye symptoms with polyunsaturated fatty acids** .....#2006-132  
 GARCHER C, PASSEMARD M, LAFONTAINE PO, VIAU S, JOFFRE C, **ELENA PP**, POULIQUEN P, BAUDOUIIN C, and BRON AM  
**Acta Ophthalmologica Scandinavica.** 2006; 84 Supplement 239 : 135

- Regard® : une enquête sur la tolérance et le confort oculaire d'une solution d'entretien pour lentilles de contact sans conservateur** .....#2005-126  
 MALET F, **CLIROPTHHA**  
*Réflexions Ophthalmol.* 2005; 84 : 62-65
- Une nouvelle méthode de mesure de la pression intraoculaire** .....#2005-125  
 DUBOIS P (a), ZEMMOURI J (b), ROULAND JF (c), and **ELENA PP** (d)  
*IRBM* 26; 4: 285-290  
 (a) Institut de technologie médicale, CHRU, Lille, France - (b) Laboratoire de spectroscopie hertzienne, USTL, Villeneuve d'Ascq, France - (c) Hôpital Huriez, Lille, France - (d) IRIS PHARMA, Nice, France
- Comparison of carteolol plasmatic levels after repeated instillations of long-acting and regular formulations of carteolol 2% in glaucoma patients** .....#2005-124  
 RENARD P (a), KOVALSKI JL (b), COCHEREAU I (c), JAULERRY S (d), WILLIAMSON W (e), **ELENA PP** (f), LABLACHE COMBIER M (g), ALLAIRE C (g), and SIOU-MERMET R (g)  
*Graefe's Arch. Clin. and Exp. Ophthalmol.* 2005; 243 : 1221-1227  
 (a) Institut Vernes, Paris, France - (b) HIA Clermont Tonnerre, Brest, France - (c) CHRU, Angers, France - (d) CH Tarbes Vic Bigorre, Tarbes, France - (e) CH François Mitterrand, Pau, France - (f) IRIS PHARMA, La Gaude, France - (g) BAUSCH & LOMB, Paris, France
- Efficacy and safety of three ophthalmic inserts for topical anaesthesia of the cornea. An exploratory comparative dose-ranging, double-blind, randomized trial in healthy volunteers** .....#2004-203  
 MAHE I (a), MOULY S (a), JARRIN I (a), OTERO J (a), TAVERA C (b), SIMONEAU G (c), TILLET Y (c), CONTI R (b), EL MESKI S (b), GAUDRIC A (a), JF BERGMANN (a)  
*Br. J. Clin. Pharmacol.* 2004; 59 : 2 220 – 226 (collaboration)  
 (a) Hôpital Lariboisière, Paris, France - (b) IOLTECH, La Rochelle, France - (c) WHITE-TILLET Consultants, Chelles, France
- Ocular hypotensive effect of a new “once-daily” eye-drops formulation of 0.5% timolol (Timolast™) in comparison to Timoptol® 0.5% administered twice-daily** .....#2004-122  
 ROULAND JF (a), **MOREL-MANDRINO P** (b), **ELENA PP** (b), DE GREGORIO F (c), BAROZZI C (c), FEDELI E (c), and FERREIRA VD (c)  
*ISOPT meeting 2004*; Monte-Carlo – Monaco  
 (a) Hôpital Huriez, Lille, France - (b) CLIROPTHHA, Nice, France - (c) TUBILUX Pharma SpA, Roma, Italy
- Intérêt d'une nouvelle formulation de diclofénac sans conservateur pour la surface oculaire** .....#2004-121  
 CHIAMBARETTA F (a), CREUZOT-GARCHER C (b), PILON F (a), POULIQUEN P (c), REBIKA H (c), DUBRAY C (d) AND RIGAL D (a)  
*J. Fr. Ophthalmol.* 2004; 27, 7, 739-744. (collaboration)  
 (a) Hôpital Gabriel Montpied, Clermont-Ferrand, France - (b) CHU de Dijon, Dijon, France - (c) Laboratoires THEA Clermont-Ferrand, France - (d) Unité de Pharmacologie Clinique, Centre de Recherche en Nutrition Humaine, Clermont-Ferrand, France
- Comparison of once-daily nonpreserved timolol and timolol maleate gel-forming solution associated with latanoprost** .....#2004-120  
 BRON A, VELASQUE L, REBIKA H, POULIQUEN P, **ELENA PP**, and ROULAND JF  
*J. Fr. Ophthalmol.* 2004; 27(9 Pt 1) : 971-7
- Non-inferiority, in the intra-ocular pressure (IOP)-lowering effect, of a new eye-drops formulation of 0.5% timolol (Timolast™) instilled once-daily versus 0.5% Timoptol®, instilled twice-daily, for 4 months in ocular hypertensive or glaucomatous patients** .....#2004-119  
 ROULAND JF, **MOREL-MANDRINO P**, DE GREGORIO F, BAROZZI C, and FEDELI E  
*ARVO meeting 2004*; Fort Lauderdale, FL – USA. *Invest. Ophthalmol. Vis. Sci.* 2004; 45 : ARVO e-abstract No. 2080
- Comparison of carteolol plasmatic levels after repeated instillations of long acting and regular formulations of carteolol 2% in glaucomatous patients** .....#2004-118  
 ALLAIRE CM, RENARD P, KOVALSKI J, COCHEREAU I, JAULERRY S, WILLIAMSON W, **ELENA PP**, and LABLACHE-COMBIER M  
*ARVO meeting 2004*; Fort Lauderdale, FL – USA. *Invest. Ophthalmol. Vis. Sci.* 2004; 45 : ARVO e-abstract No. 957
- Efficacy and safety of diclofenac 0.1% ABAK® versus preserved diclofenac® 0.1% eye drops in controlling post-cataract surgery inflammation** .....#2004-117  
 GOLDSCHMIDT P, **ELENA PP**, BALDWIN H, DELVAL L, and COLIN J  
*ARVO meeting 2004*; Fort Lauderdale, FL – USA. *Invest. Ophthalmol. Vis. Sci.* 2004; 45 : ARVO e-abstract No. 294
- Timolol 0.1% Gel (Nyogel 0.1%®) Once Daily versus Conventional Timolol 0.5% Solution Twice Daily: A Comparison of Efficacy and Safety** .....#2002-112  
 ROULAND JF (a), **MOREL-MANDRINO P** (b), **ELENA PP** (b), POLZER H (c), and SUNDER RAJ P (d)  
*Ophthalmologica* 2002; 2 16 : 449-454  
 (a) Hôpital Huriez, Lille, France - (b) CLIROPTHHA, Nice, France - (c) MEDproject Pharma, Sauerlach, Germany - (d) NOVARTIS Ophthalmics, Farnborough, UK

### A Novel Once-a-Day Timolol 0.1% Gel Formulation has an equivalent IOP-lowering efficacy to timolol 0.5% solution

#2001-109



ROULAND JF (a), MOREL-MANDRINO P (b), ELENA PP (b) and POLZER H (c)

IGS meeting 2001; Prague - Czech Republic

(a) Hpital Huriez, Lille, France - (b) CLIROPTHHA, Nice, France - (c) MEDproject Pharma, Sauerlach, Germany

### Therapeutic equivalence of a timolol 0.1% hydrogel (T-Gel 0.1%) QD and aqueous timolol 0.5% BID in reducing the IOP of glaucomatous patients

#2000-105

ELENA PP, ROULAND JF, MOREL-MANDRINO P, and POLZER H

ARVO meeting 2000; Fort Lauderdale, FL – USA. *Invest. Ophthalmol. Vis. Sci.* 2000; 41 : S281, abstract No. 2477

### Klinische und pharmakokinetische Untersuchungen zur perioperativen antiphlogistischen Wirksamkeit von Prednisolon-Gel bei der Kataraktextraktion

#1998-233

STRUKE HG, STOLDT G

Ohrloff C., Kohnen T., Duncker G. (eds) 11. *Kongreß der Deutschsprachigen Gesellschaft für Intraokularlinsen-Implantation und refraktive Chirurgie*. Springer, Berlin, Heidelberg. [https://doi.org/10.1007/978-3-642-71952-3\\_60](https://doi.org/10.1007/978-3-642-71952-3_60) (collaboration)

### Intraocular pressure effects of topical rilmenidine in ocular hypertensive animals and in healthy volunteers and glaucoma subjects

#1997-89

NORDMANN JP, ELENA PP, and VILAIN C

ISECOPP meeting 1997; Munich – Germany, p. 12

### Efficacy and local ocular tolerance of Rescula eye drops in glaucoma patients

#1997-88

NORDMANN JP, ROULAND JF, ELENA PP, and KAPOK B

ISECOPP meeting 1997; Munich – Germany, p. 27

### Rilmenidine: safety and efficacy on intraocular pressure in healthy volunteers and glaucoma patients

#1997-82

NORDMANN JP, ELENA PP, MOREL-MANDRINO P, CASTAGNE I, and VILAIN C

ARVO meeting 1997; Fort Lauderdale, FL – USA. *Invest. Ophthalmol. Vis. Sci.* 1997; 38 : S559, abstract No. 2600

### Assessment of the safety and local pharmacokinetics of 0.15 % gel of ganciclovir (Virgan®) in healthy volunteers

#1996-75

POULIQUEN P(a), ELENA PP(b), MALECAZE F(c), LUYCKX J(a), LANOUE A(a), and GOLDSCHMIDT P(d)

ARVO meeting 1996; Fort Lauderdale, FL – USA. *Invest. Ophthalmol. Vis. Sci.* 1996; 37 : S313, abstract No.1431

(a) Laboratoires THEA, Clermont-Ferrand, France - (b) CLIROPTHHA, Nice, France - (c) Hôpital Purpan, Toulouse, France - (d) Centre Hospitalier Universitaire de la Pitié-Salpêtrière, Paris, France

### Intraocular pressure effects of topical renin inhibitor CGP 38560 in normal and ocular hypertensive animals and in healthy volunteers and glaucoma subjects

#1995-72

NORDMANN JP, PERCICOT CL, ELENA PP, and MATHIS GA

ISECOPP meeting 1995; Geneva – Switzerland, p. 35

### One drop study to evaluate safety and efficacy of SR43845, a renin inhibitor, in healthy volunteers

#1995-71

DENIS P, NORDMANN JP, ELENA PP, JAILLON P, MATHIS G, and SARAUX H

ARVO meeting 1995; Fort Lauderdale, FL – USA. *Invest. Ophthalmol. Vis. Sci.* 1995; 36 : S734, abstract No. 3388

### Evaluation of safety and efficacy of CGP38560, a renin inhibitor, in healthy volunteers and glaucoma subjects

#1994-70

NORDMANN JP, DENIS P, ELENA PP, MATHIS GA, SCHNARR KD, TETZLOFF W, and KERKMANN T

ARVO meeting 1995; Fort Lauderdale, FL – USA. *Invest. Ophthalmol. Vis. Sci.* 1995; 36 : S719, abstract No. 3317

### Central nervous system control of intraocular pressure

#1994-59

DENIS P (a), NORDMANN JP (a), ELENA PP (b), SARAUX H (a), and LAPALUS P (c)

*Fundam. Clin. Pharmacol.* (France) 1994; 8 : 230-237

(a) Hôpital Saint-Antoine, dep. ophthalmology, Paris, France - (b) IRIS PHARMA, Nice, France - (c) School medicine, dep. pharmacology, Nice, France



**ABBREVIATIONS**

<b>ARVO</b>	Association for <b>R</b> esearch in <b>V</b> ision and <b>O</b> phthalmology
<b>ATERET</b>	Association Tunisienne d' <b>E</b> tude et de <b>R</b> echerche sur les <b>E</b> léments <b>T</b> races
<b>ECLSO</b>	European <b>C</b> ontact <b>L</b> ens <b>S</b> ociety of <b>O</b> phthalmologists
<b>EVER</b>	European <b>V</b> ision and <b>E</b> ye <b>R</b> esearch
<b>IGS</b>	International <b>G</b> laucoma <b>S</b> ymposium
<b>ISECOPP</b>	International <b>S</b> ymposium on <b>E</b> xperimental and <b>C</b> linical <b>O</b> cular <b>P</b> harmacology and <b>P</b> harmaceuticals
<b>ISOPT</b>	International <b>S</b> ymposium on <b>O</b> cular <b>P</b> harmacology and <b>T</b> herapeutics
<b>SAFIR</b>	Société de l' <b>A</b> ssociation <b>F</b> rançaise des <b>I</b> mplants et de la chirurgie <b>R</b> éfractive
<b>SFERETES</b>	Société <b>F</b> rancophone d' <b>E</b> tude et de <b>R</b> echerche sur les <b>E</b> léments <b>T</b> races <b>T</b> oxiques et <b>E</b> ssentiels
<b>SFO</b>	Société <b>F</b> rançaise d' <b>O</b> phthalmologie
<b>SFVB</b>	Société <b>F</b> rancophone <b>V</b> itamines et <b>B</b> iofacteurs
<b>STO</b>	Société <b>T</b> unisienne d' <b>O</b> phthalmologie